<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81863">
  <stage>Registered</stage>
  <submitdate>16/02/2007</submitdate>
  <approvaldate>19/02/2007</approvaldate>
  <actrnumber>ACTRN12607000133437</actrnumber>
  <trial_identification>
    <studytitle>Differences in weight loss using a very low energy diet in obese people with and without diabetes.</studytitle>
    <scientifictitle>In obese subjects with and without diabetes, examining the effect of a very low energy diet (VLED) on weight loss and differences in changes in cardiovascular risk, markers of oxidative stress and advanced glycation, and target organ function.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Obesity</healthcondition>
    <healthcondition>Diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A very low energy diet (Optifast). This is a meal replacement diet involving three sachets daily plus one serve of vegetables or salad (600-800kcal/day) for 12 weeks (intensive phase). Subsequently patients are weaned over 8 weeks onto a calorie controlled CSIRO-type diet.</interventions>
    <comparator>No comparator.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Lifestyle</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in body composition</outcome>
      <timepoint>At 24 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in markers of oxidative stress</outcome>
      <timepoint>At 24 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in markers of advanced glycation</outcome>
      <timepoint>At 24 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in target organ function</outcome>
      <timepoint>At 24 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Difference in weight loss</outcome>
      <timepoint>At 24 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>BMI 30 - 50 kg/m2, diabetes and no diabetes.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Thiazolidinedione therapy, significant comorbidity, previously failed VLED or bariatric surgery.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/04/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>George Jerums</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Pfizer CVL grant</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Austin Endocrine Centre research fund</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Joseph Proietto</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Obesity and type 2 diabetes increase the risk of heart, kidney and other disease. A process called oxidative stress is thought to be critical in triggering metabolic changes found in both obesity and diabetes, and thus is a major cause of developing complications from these conditions. The role of weight loss in reducing markers of oxidative stress has not been compared in obese people with and without diabetes. We predict that weight loss in obese patients with diabetes will reduce oxidative stress, and improve kidney and heart dysfunction, to a greater extent than in obese patients without diabetes.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Austin Health</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor George Jerums</name>
      <address>Endocrine Centre
Centaur Wing Repatriation Campus
Austin Health
Waterdale Rd, West Heidelberg VIC 3081</address>
      <phone>03 9496 5489</phone>
      <fax>03 9496 3365</fax>
      <email>ah-endo@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Scott Baker</name>
      <address>Endocrine Centre
Centaur Wing Repatriation Campus
Austin Health
Waterdale Rd, West Heidelberg 3081</address>
      <phone>03 9496 5489</phone>
      <fax>03 9496 3365</fax>
      <email>scott.baker@austin.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>